OOGI, MCET, CLRH, INCCE, CDXC, DNRR, AMEL, CCTR, ZVTK

I just can’t help myself!

There are so many penny stock plays that I could share with you that it is hard to limit it to these 9.   Some are the “usual suspects” i.e. ones that you see all the time (ZVTK, CCTR, AMEL) and others are new to me.

These are all penny and sub-penny stocks that are in play for reasons of news, volume or price.  Each one represents an opportunity to make money on the long or short side.  Let’s see which one works for you my readers.

Odyssey Oil & Energy Inc. (OTC: OOGI) is up 56.67% to $0.235 following the announcement of a strategic partnership with Hylem Water Ltd. The company will help Hylem raise $2.5 million in order to implement its business plan, and will take a 51% stake in the firm as a result of the transaction.  (OTC:OOGI), ($OOGI)

Great short candidate, although the stock has already fallen from its high of 30 cents intraday.  I have reviewed the PR’s and financials and there isn’t much there.  The company is still development stage in all aspects and doesn’t appear to be too close to revenues.

Still, the company does have some good prospects.  The challenge for a company like this is to stay focused enough to make at least one of their “businesses” succeed”

MultiCell Technologies Inc. (OTC: MCET) is up 38.89% to $0.0125 following the report that it was granted a European patent covering certain of its therapeutic candidates for the treatment of cancer. (OTC:MCET), ($MCET)

The granting of the European patent is big news for MCET and the market responded accordingly.  The question is with this one-day pop what will the follow up be.  The stock vaulted to $0.0178 intraday before falling back to $.014.

A big gap at open, but the potential gain was still almost 50% for the day.  I am not too impressed with MCET yet….it has several U.S. patents and it is yet to effectively commercialize them.  The Euro patents are great, but I would like to see MCET generate significant revenues before I got too excited.

Clear-Lite Holdings Inc. (OTC: CLRH) is up 46.94% to $0.360.  The company has said that it will be expanding into new lines of environmentally-friendly businesses that will provide additional revenue opportunities outside of its cutting-edge, eco-friendly lighting products.  (OTC:CLRH), ($CLRH)

International Consolidated Companies Inc. (OTC: INCCE) is up 46.15% to $0.0095 on above-average volume.  (OTC:INCCE)(OTC:INCCE)

ChromaDex Corp. (OTC: CDXC) is up 15.20% to $1.44.  The company has said that it received an investment from The Frost Group LLC, which would allow the company to pursue clinical studies and commercialization of its new pTeroPure™ pterostilbene.  (OTC:CDXC), ($CDXC)

This is one company that might be worth keeping track of.   It is already $1.44 and much of the recent good news appears burnt into the stock price.

However, their nutritional extract, pterostilbene, has enormous potential based upon what I have read and the fact that the Frost Group is “ponying up” an undisclosed amount of money.   It is being touted as the next generation “Resveratrol”.  Also, the fact that it is a nutraceutical means that approval will happen much faster than if it was a pharmaceutical.

Denarii Resources Inc. (OTC: DNRR) is up 16.67% to $0.0420.  The company has provided an update on its Chile Coal recovery project. (OTC:DNRR), ($DNRR)

Amerilithium Corp. (OTC: AMEL) is up 21.74% to $1.68 on above-average volume.  (OTC:AMEL). ($AMEL)

China Crescent Enterprises Inc. (OTC: CCTR) is down 3.24% to $0.0209.  The company has scheduled an on-demand management update Web cast for release tomorrow, April 27th.  (OTC:CCTR), ($CCTR)

Zevotek Inc. (OTC: ZVTK) is up 3.39% to $0.0061.  (OTC:ZVTK), ($ZVTK)

Don’t forget to sign up for my periodic trading alerts.  I have an awesome track record of penny stock and small cap picks that I hope you can benefit from.  Go to my signup page to sign up for my Investor Soup alerts.

Good luck and good trading,

Jeffrey Dean

Editor

^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Neither InvestorSoup.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

ARRY, IBM, NTRS, REED, KO, APH, PH, STT, SVU, ETN

The following are large and mid cap stocks that were in the news on Tuesday and might be in play for Wednesday.  My comments are indented with quotation marks.

Don’t forget to sign up for my Hot penny stock alerts?  Several times a week, I email information out to my members about micro cap stocks and penny stocks.   Once you are signed up, you will receive information on stocks trading from 1 cent to several dollars.  My focus is finding the best penny stocks that look like they are ready to move.  Sign up today!

Last week, my alert for LMCO was up over 63%.  Try and do that with AAPL!

That is just one example of how my members can benefit from my penny stock tips.

Array BioPharma Inc. (NASDAQ: ARRY) is up 32.28% to $4.00. The company has announced a $467 million cancer drug deal with Novartis. (NASDAQ:ARRY), ($ARRY)

This is huge for ARRY and is a “game changer” for the company.  However, all is not roses for ARRY.  They still are posting major losses every quarter, have high debt and are burning cash at a very high rate.  The deal is contingent on several performance benchmarks and traders got a little giddy with the stock today.

ARRY might have a day or two more run in it, but watch for it to crack because the shorters will be all over this one.

International Business Machines Corp. (NYSE: IBM) is down 2.30% to $129.19. The company has reported a 2% drop in new services contracts. (NYSE:IBM), ($IBM)

Northern Trust Corp. (NASDAQ: NTRS) is down 5.79% to $54.99 followng news of lower quarterly earnings. (NASDAQ:NTRS), ($NTRS)

Reed’s Inc. (NASDAQ: REED) is up 49.70% to $2.53. The company is seeing at least 20% increase in 2010 revenue following on record Q4 result. (NASDAQ:REED), ($REED)

The Coca-Cola Company (NYSE: KO) is down 1.72% to $54.37. The company has posted Q1 profit of $1.61 billion, 20% higher than the year-ago period. (NYSE:KO), ($KO)

Amphenol Corp. (NYSE: APH) is up 6.16% to $46.73 on stronger-than-expected Q1 results. (NYSE:APH), ($APH)

Parker-Hannifin Corp. (NYSE: PH) is up 0.39% to $69.66. The company has upped its outlook for fiscal year after reporting that Q3 profits nearly tripled. (NYSE:PH), ($PH)

State Street Corp. (NYSE: STT) is down 4.97% to $44.90 despite better earnings in Q1. (NYSE:STT), ($STT)

Supervalu Inc. (NYSE: SVU) is down 2.92% to $16.64. The company has warned that yearly profit could miss analysts’ forecasts. (NYSE:SVU), ($SVU)

Eaton Corp. (NYSE: ETN) is down 0.47% to $78.78. The company has announced a profit of $155 million in the Q1. (NYSE:ETN), ($ETN)

$ARRY, $IBM, $NTRS, $REED, $KO, $APH, $PH, $STT, $SVU, $ETN

Good luck and good trading

Jeffrey Dean

Editor

^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Neither InvestorSoup.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

MON, JCDA, BAC, AAPL, SPF, MSFT, EMAN, SNEY, BEDA, TADF

Monsanto Company (NYSE: MON) $69.01 -1.13% Monsanto reports earnings miss; warns won’t meet previously announced financial targets (NYSE:MON), ($MON)

Jacada Ltd. (NASDAQ: JCDA) $1.80 +21.63% Jacada enters into material agreement with a large U.S.-based provider of digital TV services (NASDAQ:JCDA), ($JCDA)

Bank of America Corp. (NYSE: BAC) +18.72 +1.23% Barclays analyst raises its 2010 EPS estimate for BAC (NYSE:BAC), ($BAC)

Apple Inc. (NASDAQ: AAPL) $241.10 +0.65% USPTO publishes 16 newly granted Apple patents-Report (NASDAQ:AAPL), ($AAPL)

Standard Pacific Corp. (NYSE: SPF) $5.09 +7.61% Standard Pacific shares rise on Cramer’s positive sentiment to the company (NYSE:SPF), ($SPF)

Microsoft Corp. (NASDAQ: MSFT) $29.46 +0.48% Microsoft unveils Microsoft Dynamics CRM for nonprofits and nongovernmental organizations (NASDAQ:MSFT), ($MSFT)

eMagin Corp. (OTC: EMAN) $4.38 +4.29% eMagin showcasing its advanced OLED microdisplays at the SPIE Defense, Security, and Sensing 2010 Symppsium (OTC:EMAN), ($EMAN)

Sunergy Inc. (OTC: SNEY) $0.0400 +14.29% Sunergy provides update on its petroleum supply efforts in Ghana (OTC:SNEY), ($SNEY)

Bederra Corp. (OTC: BEDA) $0.0018 +38.46% BEDA shares soar on strong volume surge (OTC:BEDA), ($BEDA)

Tactical Air Defense Services Inc. (OTC: TADF) $0.0038 +35.71% TADF shares up on higher volume (OTC:TADF), ($TADF)

________________________________________________________________________________________

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Neither InvestorSoup.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Cord Blood America was one of my best picks for 2009 (not my best, but close).  I had correctly called its September move (as the chart below will indicate).  I think that it might be time to take another look at Cord Blood America, Inc. (CBAI). Here is a link to my earlier blog.

Truthfully, it has been flogged unmercifully in the penny stock press.  It has been hailed as everything from the next Genentech to the next Spongetech.  I think the truth is somewhere in the middle.

CBAI is a stock built on hype.  It really hasn’t proven that its business model can actually work.  My wife and I have 4 kids and after each birth we were given the opportunity to harvest cord blood.  We declined each time…too expensive, the value to our children wasn’t clear in our mind, logistics of storing and accessing it….a whole host of reasons.

Having said all this, I think that CBAI might actually make it….at least long enough for traders to make some money. I have been reading the press releases and the company is taking great pains to both dazzle and teach.  Glitzy Las Vegas-style openings are contrasted with PR’s that tell of debt extinguishments, agreements signed, alliances gained, etc…  The truth is that CBAI lives a hand-to-mouth existence.  It has little or no cash and negative cash flow.  Debt is less of a problem than it was in ‘09 with some debt being retired, but they are not “out of the woods”.

I think the chart is positive and if CBAI can catch fire, I would expect to see some strong gains.

Here is the chart

CBAI seems to be consolidating at this level (as my chart indicates).    Any break below the current price of $.009 and the stock should be avoided.  I don’t believe that it will weaken, but, then again, my crystal ball is in the shop.

Good luck and good trading,

Jeffrey Dean

Editor

First a personal update:  Friday’s blog was kind of “doom and gloom” when I was stuck in the middle of a power outage (second year in a row for NH).  Even thought I got power back relatively quickly, I am still shopping online for an emergency generator.  Family is fine, house is safe and my section of NH is no longer a third-world country.  It is amazing how we take important things (like power) for granted.

Now…on to stocks.

My scans today produced NightHawk Radiology Holdings, Inc. (NHWK). Nighthawk is at the end of a prolonged decline in its stock price IMO.  This might be a good time to put it on the radar.  If it recovers from its February swoon and embarks on a climb like last year, you will like me very, very much.

Here is what I am talking about (1 yr. chart for NHWK)

NHWK is actually a very impressive company.  They have a dominant market position in their industry.  They provide services to radiology groups and hospitals throughout the United States.  NHWK provides a complete suite of solutions to doctors and hospitals, including professional services, business services, and its advanced, proprietary clinical workflow technology.  The company claims to provide round-the-clock services for for approximately 1,560 sites or 27% of all hospitals in the United States.   That is pretty impressive!

What is also impressive is that they make money.  Revenues of $162 million in ‘09, but a loss in 2009 due to a $68.7MM  goodwill impairment charge (so, I wouldn’t hold it against them).  L-T debt of $77MM, but great liquidity ratios.  Plenty of cash in the bank ($32.29MM) and over $1.37 in cash per share.

Here is the 3 month chart so traders can see in greater detail what is going on.

Here is my final analysis.  The table below is a chart of NHWK’s highs and lows during the last year.  Lots of volatility and nice bounces off lows to post highs again.  A trader could make a great profit of trading these swings.

Do you see why I say that this is a great radar stock?

I will be watching it myself.

Good luck and good trading,

Jeffrey Dean

Editor

I got an email yesterday  from one of my members (Jeff D.) asking me my opinion on what happened to Labopharm, Inc. (DDSS).  Jeff was at a loss to explain why DDSS’ shares dropped so preciptiously after getting FDA approval on one of their signature drugs.  In some ways, so am I.

Headlines like this one:

Labopharm Receives FDA Approval For OLEPTRO(TM)

usually means that a drug stock will rocket upwards.  Not in DDSS’ case.  The stock lost 40% of its value in just a few days.   Read full release here

You can see from the chart here just what I am talking about:

Stocks dropping on news of approvals is not uncommon ( see BDSI, NRIFF, PK and others), but it is still unexpected.   DDSS, the company, actually has a lot going for it.  It has income (no profits), cash in the bank, good ratios, manageable debt….and a big payday coming some time this year.  I have read where DDSS is in talks with several larger pharmaceutical firms regarding the commercialization of their newest drug, Oleptro.  I can only imagine the frenzy at DDSS offices as they take this surprise announcement and try and turn it into revenues.

I am not terribly surprised at the drop given the rise in the share price in anticipation of approval.  And, I am betting that DDSS will come back and come back strong.  Since I am a technical analyst, I will share one last chart with readers that backs up my contention.

This chart shows how volatile the stock has been and I think it is illustrative of the recuperative powers of DDSS.  You can see that the stock is trading within normal ranges and has shown great historical elasticity.  I would not be too worried about this dip and, in fact, would see this as a buying opportunity.  Having said that, there is support at $1.75 and $1.40.  I don’t think it will drop to those levels, but…you never know.

DDSS is both a short-term and a long-term hold.  In the short-term, I could see the stock regaining much of its recent losses.  It certainly seems like the sellers are out.  In the long-term, DDSS could be a “gold mine”.  I will watch with great interest for news on how they will commercialize this and what the financial ramifications are for the company.

I didn’t spend any time in this blog on drug pipelines and other pharma standards.  I expect that my readers will do their own DD.  Here is DDSS’s website link for your own research.

Trade like you mean it!

Jeffrey Dean

Editor-in-Chief

Note on 2/12/10:  DDSS is getting hammered.  The market did not like the news of their $20MM  offering.   DDSS blew through the $1.75 support and is headed down to the $1.40 level.  MIght be best to take an EVEN more cautious approach to this one.

I myself have trouble keeping track of all of the penny stocks and small cap stocks that I am watching, have blogged or issued alerts on.  I am trying out a feature that will be a part of my site going forward (I hope).  I want to list the stocks that I am following…. a watch list, per se.  These are stocks that I think that traders should be aware of.  Some continued to drop after I profiled them, but still present a good opportunity and other are on the “launching pad ready to take off” IMHO.

Without further ado:

VIVK - Vivakor, Inc. is one of those stocks that has been very frustrating.  I still like the company (here is a link to my original blog), but have seen it slide gradually from 14/15 cents at the time of my blog to as low as 12 cents.  It has recovered and closed yesterday around 14 cents.  VIVK still has great promise, but it is getting hammered by market conditions and trader apathy.  Here is a link to their chart.

CMIN - Constitution Mining is another of those frustrating picks for me.  I like the company, it has issued positive news, but it continues to fall.  So much so, in fact, that my trading stop got triggered and I sold out of my stock yesterday.  I am going to continue to monitor it to see about getting back in.  I still like the company (read my blog) and here is a link to a detailed chart for CMIN.

BZH - Beazer Homes, Inc. is a stock that I haven’t blogged, but came across yesterday doing my stock screens.  It has had a strong bearish run, but could be poised to recover.  They are a home builder (one of the biggest) and they have managed to stay in business, service debt and continue to build houses.  They should get a medal for that!  With bad news in the housing sector, they have taken a hit.  I think they can recover.  They look to be building a base at current levels (around $4.07), but any break below this price and it should be avoided.  Here is a link to BZH chart

LGDI - Legend International has been a good trader for Soupies (I even made some good profits trading it myself).  After my second blog on LGDI at 75 cents, the stock ROARED to a high of $1.60.  The stock has given about 25% of its value back recently, but now looks primed to resume its upward march.  It has been named on several lists as a “stock to watch” for 2010 and I am in agreement.  Here is a link to LGDI’s current chart.

AOB - Yesterday’s blog topic and a “great trader”.  Link to AOB’s blog right here!

I will add other stocks to this list as I think of them.

Disclosure: Long VIVK

******************************************************************************************************

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Neither InvestorSoup.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

I was tempted to have a title that said something like “Helix Wind…that company really blows”, but I thought better of it. That wouldn’t be too professional.  I am serious, however, when I say that my readers should take a look at the company.

Helix Wind Corporation (HLXW) is engaged in the design, manufacturing and sale of “small wind” vertical axis turbines (VAWT) designed to generate clean, renewable electricity from wind.  The key for HLXW is the term “small wind”.   The company makes its case for the small wind strategy on its site:

“Small (or “residential”) wind energy systems typically generate just enough power to meet the demands of a home, farm or small business. They range from 400 watts to 500 kilowatts or more and typically consist of a single turbine (vertical or horizontal). They can be significant power sources and have proven records of performance, even in locations with modest winds.”

Here is graphic evidence on how they are different:

This is not the typical propeller blade turbine that is used on the wind farm installations that are so popular these days. This is a uniquely designed, niche product that is scalable from a single residence (the S322) to the D15000 which produces enough electricity for 10 homes or a medium size commercial facility.   Helix believes that the VAWT configuration is superior due to the fact that functions in wind that comes from all directions and is well suited to gusty wind conditions which typical blade wind turbines are not.

Here is a link to HLXW’s website. It is a very well done site and has a great deal of interesting information on it.  They also have a Fact Sheet nested on their site that makes for good reading.

Now, lets talk about the company and the chart. The company is long on promise and good news, but short on cash.  While the company is booking revenues, it is losing millions of $ every quarter.  The Balance Sheet is no help.  The company is essentially insolvent according to their last quarterly statement.  I have confirmed that the company is raising capital and is actually in a “quiet period” before the announcement which could happen as early as next month.  The key shareholders are subject to a lock-up of their shares in conjunction with the capital raise.

The company has released info on potential orders, but it is sparse.  The Argentinian deal sounds good for the company, but near term it doesn’t appear to help too much.  I would like to see more press releases about sales and distribution.   The company has not issued revenue guidance for 2010 yet, but says they plan to later in the year once the financing is wrapped up and at least one more acquisition is closed.

The chart makes for interesting study:

HLXW is a company worth watching. The stock may have farther to fall based upon momentum and trend lines.  In their industry, there is no market leader in the small wind category.  HLXW wants to become that market leader and in my conversations with the company, they feel that it can be achieved.   Certainly, government and utility subsidies and credits will continue to help drive wind power forward.   But, HLXW has to achieve their financing goals first before “world domination” is possible.

Honestly, I have fallen in love with the product and think that, on its face, it makes a great deal of sense for the market.  If the company wants to install a Helix wind turbine on my house, I will love them even more.

Good luck and good trading,

Jeffrey Dean

Editor

****************************************************************************************************

RGEN posted a 52-week low on Friday and appears to be losing the hearts and minds of investors.  Could be a good time to invest!

Repligen Corporation (RGEN) is a biopharmaceutical company focused on the development of novel therapeutics for neurological disorders.  It is unique in the world of biopharma for several reasons…it has significant income already and it is sitting on a huge amount of cash.  Biopharma companies are traditionally very volatile.  Well, the pendulum for RGEN has been swinging the wrong way for quite a while.  I would not be surprised to see that pendulum swing back.

The news that “drove a stake in theheart” of RGEN’s stock price was the news that one of their drugs, a pancreas imaging agent designated RG1068, did not meet its main goal in a late-stage clinical study.  In an overreaction typical of the biopharma space, the stock tanked.  While the company tried to put a positive spin on it, it was clear that the drug has problems.  According to the company, they will determine the drug’s future after discussions with the FDA in early 2010.

What this news overshadowed, in my mind, is that RGEN is SO MUCH MORE than just this one drug.  Fiscal year end 2008 and 2009 (March 31st) showed a profit for the full year.  While the company is operating at a Quarter-over-Quarter loss this year, the company is on a run rate to book revenues of over $20MM.  The company has an absolutely ROCK SOLID balance sheet….cash and equivalents of over $42MM and NO LONG TERM DEBT.

RGEN’s recent news hasn’t been all bad either. Shortly after the RG1068 announcement, RGEN ann0unced the the Muscular Dystrophy Association (MDA) awarded them a grant for $731,000 for further research into new treatments for Friedreich’s ataxia.  This grant will support the completion of preclinical GLP toxicology testing and GMP manufacture of a drug candidate for human clinical trials.  The company believes that this funding is significant because it is evidence of support from the MDA not only provides important funding for Repligen’s research but it also provides access to a global network of scientists, physicians and patients.  This is the second research grant that RGEN has received from the MDA to support its Friedreich’s ataxia program.

To the Chart!

Clearly, RGEN is on a negative trend and no one call a bottom.  However, the stock bears watching.  It has the kind of balance sheet, revenue stream, position in the industry that makes me believe that this dip in stock price could only be temporary.  It has heavy insider and institution ownership, the short percentage is under 5% and is sitting on lots of cash.

Radar RGEN.…any good news will easily recover the lost value in the shares and the company has the financial wherewithal to “stay in the game” for a long, long time.

Good luck and good trading,

Jeffrey Dean, Editor

*******************************************************************************************************

<!– /* Font Definitions */ @font-face {font-family:”Cambria Math”; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-1610611985 1107304683 0 0 159 0;} @font-face {font-family:Verdana; panose-1:2 11 6 4 3 5 4 4 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:536871559 0 0 0 415 0;} /* Style Definitions */ p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:”"; margin:0in; margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:10.0pt; font-family:”Times New Roman”,”serif”; mso-fareast-font-family:”Times New Roman”;} .MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-size:10.0pt; mso-ansi-font-size:10.0pt; mso-bidi-font-size:10.0pt;} @page Section1 {size:8.5in 11.0in; margin:1.0in 1.25in 1.0in 1.25in; mso-header-margin:.5in; mso-footer-margin:.5in; mso-paper-source:0;} div.Section1 {page:Section1;} –>

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Neither InvestorSoup.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Today’s alert company has assembled a seemingly unrelated group of companies and technologies under its corporate umbrella. In reality, they have created a potential new media powerhouse that will deliver information, entertainment and services to its growing customer base through the Internet and mobile devices.

My next trade alert today is on is:  Metraton, Inc. (MRNJ)

MRNJ is a diversified new media company that is focused on mobile phone applications (apps) and Web 2.0 services and products.

They are currently configured in four functional divisions (with more to come):

• Online dating through its subsidiary CupidsDevil, Inc.
• Credit card processing through JustData Inc.
• Next-gen relational database development and search engine advertising optimization through PB Magic Inc.
• Iphone/mobile device applications through via i-Mobilize, Inc.

MRNJ, as a private company, states that they have a long, successful history in their marketplace.  Over their history they have:

• Serviced thousands of Internet customers

• Remained virtually debt-free with a very low overhead structure

• Generated millions in revenue

• Maintained a profit margin of over 30%

Now, as a public company, MRNJ has some very lofty goals and some strong momentum.  The company has coined a phrase to explain its corporate acquisition strategy: “Build—Acquire- Monetize”.  This strategy involves ACQUIRING and ASSIMILATING fast growing companies and technologies in the hottest technology and entertainment sectors, forming a broad, but very focused network allowing MRNJ to leverage the strengths of these components to develop strong, profitable companies.

I mentioned growth several times already in my writeup….here are some of the headlines that lead me to believe that the company will be able to deliver on its claims of growth.

Headline #1:

Just a couple of days ago, MRNJ announced it had entered into a mobile distribution agreement with Momentum Entertainment and Sports Network, LLC. (MESN)

The venture will include a series of iPhone and Droid applications for MESN’s popular sports, reality, and lifestyle TV shows including Destination-X, Zone-X and Josh and JB.

MESN is a leading provider of entertainment and sports programming which to date has distributed over 180 episodes of High Definition programming through CBS, NBC, CW, Syndicated TV, AOL Video, Hulu.com, and MRNJ may, with its new agreement, have access to a network reaches over 50 countries worldwide and and over 650 Million mobile phones.

“This major agreement moves i-Mobilize one step closer to reaching its goal of being the fourth largest distributor of mobile content by Spring 2010, behind only Google, Apple and Amazon” said Joe Riehl, Metraton CEO .” To read the full release: Click Here.

Headline #2:

MRNJ also just announced that a new agreement with Digital Management Associates LLC will enable the two companies to bring thousands of classic movie and television shows to your mobile phone!

Metatron CEO Riehl explained, “Our first iPhone Video Delivery app has been submitted and APPROVED by Apple, and we have dozens of titles on sale NOW. While we certainly are not yet a household name like Netflix or Blockbuster, we can now bring classic movie content to millions of mobile devices, and expect to be releasing thousands of titles in the coming months.” To read the full release: Click Here.

Just so you realize the scope of this revelation: It is estimated that over $200 MILLION of iPhone applications are sold monthly.

I highly recommend that members take a peek at CNBC’s feature “Planet of the APPS” to get an idea of how pervasive (make that HUGE) the app market is! Planet of the Apps

The Chart!

Looking at MRNJ’s chart tells a very interesting story. It appears that the “January effect” is taking place for the stock.  After a year-end selloff that hammered the stock price, the stock has recovered around 50% of the decline and could be poised to continue its advance.  The annotated chart below lays out what I am seeing with this chart.

People that I know in this industry (wiser than me) always agree that it is smart to “ride the trend”. Even though MRNJ has had a great run lately, the bullish trend may mean that this one has farther to go.  If you trade it, make sure that you put a tight stop on it and a trailing stop to capture gains if it takes off.

Do your due diligence carefully, but be sure to get this one on your radar.

Good luck and good trading!!!

___________________________________________________________________________